1. PCSK9 Inhibitors and Real-World Evidence

3. When to Consider Nonstatin Therapy

4. Nonstatin Recommendations From Treatment Guidelines

5. Beyond Statins – AHA/ACC 2018 Lipid Updates

6. PCSK9 Inhibitors FDA Indications

7. PCSK9 Inhibitors Dosing and Administration

8. FOURIER Outcomes Trial Evolocumab

9. FOURIER Efficacy Outcomes

10. FOURIER Safety

11. FOURIER Total Primary Endpoint Events

12. ODYSSEY Outcomes Study Alirocumab

13. Alirocumab ODYSSEY Outcomes Trial Results

14. OSLER-1 Trial

15. High-Risk Groups for Future ASCVD Events 2018 ACC/AHA Cholesterol Guidelines

16. FOURIER Trial PAD Subgroup Analysis

17. Who Will Benefit Most From "Lowest Is Best" Strategy?

18. Statin-Associated Muscle Symptoms vs Statin Intolerance

19. Identify Patients With Statin Intolerance

20. Statins and Glucose Homeostasis Perception vs Evidence

21. Improving PCSK9 Inhibitor Approval Rates

22. Navigating the Prior Authorization Process With the Patient

23. Navigating the Prior Authorization Process Clinical Pearls

24. Clinical Tips for Therapeutic Management of PCSK9 Inhibitors

25. Conclusion

26. Abbreviations

27. Abbreviations (cont)